04 Jun
2018
16:30 E.S.T.

FDA Grants Cellectis IND Approval for UCART22 in B-ALL

Read more

22 May
2018
19:15 E.S.T.

Approval of UCART123 Amendment in AML to Accelerate Clinical Development

Read more

22 May
2018
16:00 E.S.T.

Calyxt Announces Successful Closing of $60.9 Million Public Offering

Read more

21 May
2018
08:30 E.S.T.

Calyxt Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Read more

18 May
2018
08:55 E.S.T.

Calyxt Announces Upsizing and Pricing of Follow-On Offering

Read more

15 May
2018
17:45 E.S.T.

Calyxt Announces Launch of Proposed Follow-On Offering

Read more

10 May
2018
17:15 E.S.T.

Cellectis to Present Data at the 2018 ASGCT Annual Meeting

Read more

07 May
2018
16:30 E.S.T.

Cellectis Reports 1st Quarter 2018 Financial Results

Read more

02 May
2018
16:30 E.S.T.

Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL)

Read more

01 May
2018
07:00 E.S.T.

Harvard’s Wyss Institute partners with Cellectis to recode the human genome

Read more